- POSITIVE
Annual Revenue Vaidya Sane Ayurved Mar-2026 Annual Revenue is Rs 102 Cr which is growth of 14.5% YoY.
- POSITIVE
Annual Net Profit Vaidya Sane Ayurved Mar-2026 Annual Net Profit is Rs 5 Cr which is growth of 0.8% YoY.
NSE: MADHAVBAUG
Vaidya Sane Ayurved Live Share Price Today, Share Analysis and Chart
aboutVaidya Sane Ayurved Laboratories Ltd., known commercially as Madhavbaug, is a specialist healthcare provider in India focusing on the treatment of lifestyle-related chronic diseases, particularly cardiac ailments, through a combination of Ayurved... Read More
136.000.00(0.00%)
1,200
NSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Please subscribe to view forecaster data
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
6Positive10Negative
37.5%Pass in checklist
Check P/E Buy Sell Zone
Not enough data available
Vaidya Sane Ayurved Stock Price Analysis
Week Price Range-7.1% 1 Week return | 136 (LTP) 134150 LowHigh |
|---|---|
Month Price Range-19.0% 1 Month return | 136 (LTP) 134179.7 LowHigh |
52 Week Price Range-49.6% 1 Year return | 136 (LTP) 134335 LowHigh |
Competitors/Peers
Revenue Mix
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Vaidya Sane Ayurved annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.5% | 14.2% | 101.8 | 88.9 | 98.9 | 100.4 | 75.1 | 52.3 | 75.3 | 62.6 | 37.7 | ||
Operating Exp. Ann. | -0.5% | 13.4% | 89.3 | 77 | 94.2 | 90.7 | 67.8 | 47.7 | 71.9 | 59.1 | 35.3 | |
Operating Profit Ann. | 7.5% | 17.5% | 10.3 | 10.1 | 3.2 | 8.3 | 6.9 | 4.6 | 3.3 | 3.4 | 2.4 | |
OPM Ann. % | 6.9% | 2.8% | 10.14% | 11.40% | 3.21% | 8.30% | 9.21% | 8.84% | 4.43% | 5.50% | 6.32% | |
0.8% | 13.5% | 95.7 | 80.8 | 97.4 | 93.5 | 70.3 | 50.7 | 75.1 | 61.2 | 36.3 | ||
EBITDA Ann. | 8.8% | 22.1% | 12.5 | 11.9 | 4.7 | 9.7 | 7.3 | 4.6 | 3.4 | 3.5 | 2.4 | |
EBITDA Ann. margin % | 8.4% | 6.8% | 12.29% | 13.39% | 4.78% | 9.66% | 9.66% | 8.85% | 4.52% | 5.62% | 6.46% | |
Interest Ann. | 58.7% | 5.9% | 0.8 | 0.1 | 0.3 | 0.2 | 0.2 | 0.6 | 0.9 | 0.6 | 0.1 | |
Depr. | 29.1% | 17.5% | 5.6 | 3.7 | 3 | 2.6 | 2.3 | 2.5 | 2.2 | 1.6 | 0.9 | |
PBT Ann. | -4% | 30.7% | 6.1 | 6.9 | 1.5 | 6.9 | 4.8 | 1.6 | 0.2 | 1.4 | 1.4 | |
Tax Ann. | -11% | 64.4% | 1.2 | 2 | 0.4 | 1.7 | 1.3 | 0.1 | 0.1 | 0.4 | 0.4 | |
-2% | 25.1% | 4.9 | 4.9 | 1 | 5.2 | 3.5 | 1.6 | 0.1 | 1 | 1.1 | ||
Net Profit Ann. | -2% | 65.1% | 4.9 | 4.9 | 1 | 5.2 | 3.5 | 0.4 | 0.1 | 1 | 1.1 | |
NPM Ann. % | -1.9% | 46.2% | 4.95% | 5.62% | 1.07% | 5.24% | 4.64% | 0.74% | 0.16% | 1.55% | 2.83% | |
EPS Adj. latest Ann. | -1.4% | 63.7% | 4.7 | 4.7 | 1 | 4.9 | 3.3 | 0.4 | 0.1 | 0.9 | 1 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
14.5%
2Y CAGR
1.5%
3Y CAGR
0.5%
5Y CAGR
14.2%
7Y CAGR
7.2%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
2Y CAGR
121.4%
3Y CAGR
-2%
5Y CAGR
65.1%
7Y CAGR
25.5%
Net Profit Annual growth is stable compared to historical averages.
Operating Exp. Ann.
1Y CHG
16%
2Y CAGR
-2.6%
3Y CAGR
-0.5%
5Y CAGR
13.4%
7Y CAGR
6.1%
Operating Expenses Annual Cr growth is higher than historical averages.
Vaidya Sane Ayurved Technical Analysis
Vaidya Sane Ayurved EMA & SMA
Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
| 5 Day | 140.7 |
|---|---|
| 10 Day | 147.1 |
| 12 Day | 149.0 |
| 20 Day | 154.4 |
| 26 Day | 157.1 |
|---|---|
| 50 Day | 164.7 |
| 100 Day | 177.2 |
| 200 Day | 191.7 |
Vaidya Sane Ayurved Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 2026100.0%
Week82.4%
Month93.5%
Vaidya Sane Ayurved Active Candlesticks
Long Legged Doji Uptrend Gravestone Doji
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Vaidya Sane Ayurved Resistance and Support
140.67
Pivot
| First Resistance | 145.3 |
|---|---|
| Second Resistance | 154.7 |
| Third Resistance | 159.3 |
| First Support | 131.3 |
|---|---|
| Second Support | 126.7 |
| Third Support | 117.3 |
| Day RSI | 26.2 |
|---|---|
| Day MACD | -8 |
| Day MFI | 19.8 |
| Day MACD Signal Line | -5.1 |
Vaidya Sane Ayurved Beta
| 1 Month | 0.9 |
|---|---|
| 1 Year | 0.0 |
| 3 Month | 0.5 |
|---|---|
| 3 Year | 0.0 |
Vaidya Sane Ayurved Price Change Analysis
↓-19.0%
Over 1 Month
LowHigh
134179.7
↓-29.1%
Over 3 Months
LowHigh
134194
↓-43.7%
Over 6 Months
LowHigh
134294
↓-49.6%
Over 1 Year
LowHigh
134335
Vaidya Sane Ayurved Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| VINAYAK G KUDVA | Bulk | Sell | 06 May 2026 | 280 | 130,000 | NSE |
| DHYANAM CAPITAL | Bulk | Purchase | 24 Feb 2022 | 101.90 | 152,000 | NSE |
| SHARAD HARLALKA | Bulk | Purchase | 23 Feb 2022 | 106.94 | 64,000 | NSE |
| DHYANAM CAPITAL | Bulk | Purchase | 23 Feb 2022 | 101.77 | 264,000 | NSE |
Vaidya Sane Ayurved Corporate Actions
Vaidya Sane Ayurved Dividend history and yield
Vaidya Sane Ayurved dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Vaidya Sane Ayurved dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
118 Nov 2022 | 0.25 | INTERIM | 18 Nov 2022 | Equity Share |
Vaidya Sane Ayurved Board Meetings
Vaidya Sane Ayurved past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
115 May 2026 | Audited Results | - |
205 Nov 2025 | Quarterly Results | - |
322 May 2025 | Audited Results | (Revised) |
411 Nov 2024 | Quarterly Results & Others | To consider other business matters. |
526 May 2024 | Audited Results | - |
Vaidya Sane Ayurved - Company Profile
Vaidya Sane Ayurved Management Structure
Vaidya Sane Ayurved management structure with salaries, total experience, and qualifications.
Vaidya Sane Ayurved Board of Directors
Vaidya Sane Ayurved Board of directors with salaries, total experience, and qualifications.
Website: www.madhavbaug.org
About the company - Business Profile
Vaidya Sane Ayurved Laboratories Ltd., known commercially as Madhavbaug, is a specialist healthcare provider in India focusing on the treatment of lifestyle-related chronic diseases, particularly cardiac ailments, through a combination of Ayurveda and modern medical diagnostics. The company operates a network of multidisciplinary clinics and hospitals that provide non-invasive treatments for heart disease, diabetes, hypertension, and obesity. Positioned at the intersection of traditional wellness and evidence-based medicine, it provides a structured "reversal" program for chronic conditions using proprietary Ayurvedic formulations and therapeutic procedures.
Key Points
- Key Facts: Founded in 1999 and headquartered in Thane, Maharashtra, the company is listed on the NSE SME platform. Its primary brand, Madhavbaug, serves as the face of its clinical and hospital operations.
- Operations and Resources: The company operates two main cardiac hospitals (in Khopoli and Kondali) and a vast network of over 350 clinics across India, including both company-owned and franchised models. These facilities are integrated with diagnostic services and an e-pharmacy platform.
- Business Model: Madhavbaug follows a service-oriented model centered on chronic disease management. It excels in non-invasive cardiac care, utilizing its "Sampurna Hriday Shuddhikaran" (SHS) therapy. Revenue is generated through clinical consultation fees, specialized Ayurvedic procedures, and the sale of health supplements and medicines.
- Revenue Breakdown: For the financial year ending March 31, 2025, the company reported total revenue from operations of INR 112.51 Crore, compared to INR 94.75 Crore in the previous year, reflecting a growth of approximately 18.7%. Revenue is primarily derived from:
- Clinical and Hospital Services: Fees for cardiac and diabetic reversal programs.
- Product Sales: Sale of proprietary Ayurvedic medicines and healthcare products.
- Key Products and Technology:
- SHS Therapy: A proprietary procedure-based treatment for heart blockages and congestive heart failure.
- Madhavbaug App (mIBE): A digital health platform used for real-time monitoring of patient vitals and treatment adherence, enabling a "hospital-at-home" approach.
- Diagnostic Integration: Use of modern diagnostics like Stress ECG and VO2 Max testing to quantify the effectiveness of Ayurvedic treatments.
- Strategic Initiatives: The company is currently focused on expanding its geographical footprint into North and South India. It is also investing in clinical research to publish peer-reviewed studies on its treatment outcomes to enhance medical credibility.
- Human Capital: As of the end of FY2025, the company employs over 800 personnel, including a large team of BAMS (Ayurveda) doctors trained in modern cardiac diagnostics.